TRVI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 24.37%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $349,116.96

Trevi Therapeutics Insider Trading History Chart

Trevi Therapeutics Share Price & Price History

^$2.77

▼ -0.23 (-7.67%)

As of 11/20/2024 01:00 AM ET

Days: 30 | 90 | 365

Blackrock’s Sending THIS Crypto Higher on Purpose

From Crypto 101 Media | Ad

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

YES, I WANT THE #1 CRYPTO NOW

Trevi Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/9/2024	Jennifer L Good	CEO	Sell	1,840	$3.04	$5,593.60	213,313
9/6/2024	Jennifer L Good	CEO	Sell	4,219	$3.03	$12,783.57	213,313
9/4/2024	Jennifer L Good	CEO	Sell	10,981	$3.02	$33,162.62	213,313
8/27/2024	David P Meeker	Director	Sell	4,555	$2.93	$13,346.15	352,489
8/16/2024	Thomas Sciascia	Insider	Sell	18,660	$2.76	$51,501.60	220,315
8/14/2024	Thomas Sciascia	Insider	Sell	100	$2.75	$275.00	220,315
5/29/2024	Thomas Sciascia	Insider	Sell	53,368	$2.55	$136,088.40	214,433
5/22/2024	Lisa Delfini	CFO	Sell	4,350	$2.64	$11,484.00	53,279
5/20/2024	Jennifer L Good	CEO	Sell	25,037	$2.86	$71,605.82	213,313
5/10/2024	Jennifer L Good	CEO	Sell	4,578	$2.90	$13,276.20	213,313
10/11/2023	Lisa Delfini	CFO	Sell	785	$2.02	$1,585.70	35,901
9/11/2023	Lisa Delfini	CFO	Sell	711	$2.20	$1,564.20	34,394
8/11/2023	Lisa Delfini	CFO	Sell	682	$2.36	$1,609.52	32,814
7/11/2023	Lisa Delfini	CFO	Sell	687	$2.34	$1,607.58	31,204
6/12/2023	Lisa Delfini	CFO	Sell	610	$2.64	$1,610.40	29,599
4/11/2023	Lisa Delfini	CFO	Sell	840	$1.84	$1,545.60	26,189
3/13/2023	Lisa Delfini	CFO	Sell	892	$1.75	$1,561.00	24,737
2/13/2023	Lisa Delfini	CFO	Sell	8,474	$2.45	$20,761.30	23,338
7/5/2022	Tpg Gp A, Llc	Major Shareholder	Sell	63,569	$3.11	$197,699.59	3,824,883
7/1/2022	Tpg Gp A, Llc	Major Shareholder	Sell	436,431	$2.86	$1,248,192.66	3,888,452
6/29/2022	Tpg Gp A, Llc	Major Shareholder	Sell	46,128	$2.74	$126,390.72	4,754,721
5/2/2022	Tpg Gp A, Llc	Major Shareholder	Sell	600	$2.70	$1,620.00	4,800,849
4/28/2022	Tpg Gp A, Llc	Major Shareholder	Sell	7,271	$2.77	$20,140.67	4,817,612
4/11/2022	Paul Edward Walker	Major Shareholder	Buy	3,580,526	$1.90	$6,802,999.40	10,421,428

I was wrong. Dead wrong.

From Porter & Company | Ad

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

SEC Filings (Institutional Ownership Changes) for Trevi Therapeutics (NASDAQ:TRVI)

95.76% of Trevi Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Trevi Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/19/2024	Barclays PLC	95,232	$0.32M	0.0%	+180.8%	0.124%
11/16/2024	Geode Capital Management LLC	1,264,166	$4.22M	0.0%	+10.2%	1.645%
11/15/2024	Barclays PLC	95,232	$0.32M	0.0%	+180.8%	0.124%
11/15/2024	Jane Street Group LLC	32,929	$0.11M	0.0%	-50.4%	0.043%
11/15/2024	State Street Corp	952,912	$3.18M	0.0%	+5.9%	1.240%
11/15/2024	Checkpoint Capital L.P.	250,000	$0.84M	0.4%	-50.0%	0.325%
11/14/2024	Fred Alger Management LLC	76,544	$0.26M	0.0%	N/A	0.100%
11/14/2024	Ally Bridge Group NY LLC	1,322,800	$4.42M	2.4%	-10.3%	1.721%
11/14/2024	Acuta Capital Partners LLC	290,500	$0.97M	0.8%	+11.7%	0.378%
11/13/2024	BNP Paribas Financial Markets	11,930	$40K	0.0%	+130.9%	0.016%
11/9/2024	Landscape Capital Management L.L.C.	424,725	$1.42M	0.1%	-29.8%	0.585%
11/9/2024	Intech Investment Management LLC	18,914	$63K	0.0%	N/A	0.026%
11/7/2024	MAI Capital Management	1,327,285	$4.43M	0.0%	+0.7%	1.828%
11/6/2024	Oppenheimer & Co. Inc.	81,947	$0.27M	0.0%	+34.7%	0.113%
11/5/2024	GSA Capital Partners LLP	122,447	$0.41M	0.0%	N/A	0.169%
10/30/2024	Rosalind Advisors Inc.	750,000	$2.51M	1.6%	-46.1%	1.033%
10/3/2024	SG Americas Securities LLC	23,405	$78K	0.0%	N/A	0.033%
8/15/2024	The Manufacturers Life Insurance Company	24,524	$73K	0.0%	+87.6%	0.035%
8/14/2024	Logos Global Management LP	2,800,000	$8.34M	0.7%	+27.3%	3.975%
8/14/2024	Ally Bridge Group NY LLC	1,474,926	$4.40M	2.6%	N/A	2.094%
8/13/2024	Rubric Capital Management LP	5,026,931	$14.98M	0.4%	-9.7%	7.137%
8/12/2024	Hsbc Holdings PLC	19,612	$61K	0.0%	N/A	0.028%
8/9/2024	Renaissance Technologies LLC	51,900	$0.16M	0.0%	-55.6%	0.074%
8/9/2024	Dimensional Fund Advisors LP	72,210	$0.22M	0.0%	+217.6%	0.103%
8/8/2024	American Century Companies Inc.	54,108	$0.16M	0.0%	+17.1%	0.077%
8/1/2024	Rhumbline Advisers	75,218	$0.22M	0.0%	+44.8%	0.107%
7/26/2024	Bank of New York Mellon Corp	178,511	$0.53M	0.0%	+38.8%	0.253%
7/12/2024	Rosalind Advisors Inc.	1,391,577	$4.15M	3.0%	+50.3%	1.976%
5/29/2024	Opaleye Management Inc.	2,645,000	$9.13M	2.0%	+4.3%	3.756%
5/15/2024	Price T Rowe Associates Inc. MD	13,561	$47K	0.0%	N/A	0.019%
5/14/2024	Propel Bio Management LLC	260,000	$0.90M	0.5%	N/A	0.369%
5/10/2024	Vanguard Group Inc.	2,303,648	$7.95M	0.0%	+2.7%	3.271%
5/7/2024	Oppenheimer & Co. Inc.	60,415	$0.21M	0.0%	N/A	0.086%
5/7/2024	SG Americas Securities LLC	14,592	$50K	0.0%	-85.1%	0.021%
5/1/2024	BNP Paribas Financial Markets	20,577	$71K	0.0%	-84.4%	0.030%
4/25/2024	Rosalind Advisors Inc.	926,016	$3.20M	3.0%	-50.3%	1.343%
2/15/2024	Opaleye Management Inc.	2,535,000	$3.40M	0.9%	+48.6%	3.970%
2/15/2024	Frazier Life Sciences Management L.P.	7,381,090	$9.89M	0.5%	+7.3%	11.559%
2/5/2024	WealthTrust Axiom LLC	63,500	$85K	0.0%	-32.1%	0.099%
1/12/2024	SG Americas Securities LLC	98,253	$0.13M	0.0%	+401.4%	0.154%
1/4/2024	Trust Co. of Toledo NA OH	36,502	$49K	0.0%	-68.8%	0.057%
11/13/2023	Silverarc Capital Management LLC	927,415	$2.02M	0.6%	+4.7%	1.452%
10/20/2023	Trust Co. of Toledo NA OH	117,145	$0.26M	0.1%	-6.2%	0.183%
10/13/2023	SG Americas Securities LLC	19,597	$43K	0.0%	N/A	0.031%
9/21/2023	Barclays PLC	14,052	$34K	0.0%	N/A	0.022%
8/11/2023	VR Adviser LLC	3,422,397	$8.18M	1.3%	+12.2%	5.697%
8/11/2023	Tejara Capital Ltd	180,227	$0.43M	0.2%	-5.3%	0.300%
8/4/2023	American International Group Inc.	20,037	$48K	0.0%	N/A	0.033%
8/3/2023	Innovis Asset Management LLC	43,232	$0.10M	0.0%	-50.5%	0.072%
8/2/2023	MAI Capital Management	1,534,652	$3.67M	0.1%	-4.1%	2.555%
7/10/2023	Trust Co. of Toledo NA OH	124,857	$0.30M	0.1%	+50.4%	0.208%
5/12/2023	Tejara Capital Ltd	190,218	$0.35M	0.2%	+26.8%	0.317%
5/10/2023	MAI Capital Management	1,600,415	$2.96M	0.0%	-7.0%	2.664%
4/4/2023	Trust Co. of Toledo NA OH	83,000	$0.15M	0.0%	N/A	0.138%
2/10/2023	Opaleye Management Inc.	485,000	$0.94M	0.3%	N/A	0.809%
2/9/2023	MAI Capital Management	1,720,676	$3.32M	0.1%	-14.8%	2.872%
2/3/2023	Frazier Life Sciences Management L.P.	6,663,590	$12.86M	0.8%	+23.3%	11.121%
2/2/2023	Bailard Inc.	21,200	$41K	0.0%	N/A	0.035%
2/1/2023	Bank of Montreal Can	152,300	$0.29M	0.0%	N/A	0.254%
11/15/2022	TPG GP A LLC	251,780	$0.39M	0.0%	-94.2%	0.571%
11/14/2022	Armistice Capital LLC	864,000	$1.33M	0.0%	+107.7%	1.961%
11/14/2022	Altium Capital Management LP	1,066,157	$1.64M	0.6%	-17.0%	2.419%
11/14/2022	Rubric Capital Management LP	5,684,420	$8.75M	0.4%	+219.6%	12.899%
11/10/2022	Hillsdale Investment Management Inc.	86,531	$0.13M	0.0%	N/A	0.196%
11/9/2022	Fairmount Funds Management LLC	5,696,515	$8.77M	1.5%	+250.7%	12.926%
11/7/2022	Jump Financial LLC	42,977	$66K	0.0%	N/A	0.098%
10/28/2022	Silverarc Capital Management LLC	939,265	$1.45M	0.5%	N/A	2.131%
8/15/2022	Acuta Capital Partners LLC	35,000	$98K	0.1%	N/A	0.090%
8/10/2022	Frazier Life Sciences Management L.P.	1,171,627	$3.29M	0.3%	N/A	3.029%
7/27/2022	WealthTrust Axiom LLC	93,500	$0.26M	0.1%	-5.1%	0.242%
7/19/2022	MAI Capital Management	2,040,009	$5.73M	0.1%	+32.3%	5.273%
5/10/2022	MAI Capital Management	1,541,471	$3.39M	0.1%	N/A	3.985%
5/9/2022	WealthTrust Axiom LLC	98,500	$0.22M	0.1%	+245.6%	0.255%
5/4/2022	Commonwealth Equity Services LLC	15,000	$33K	0.0%	N/A	0.049%
8/17/2021	Bridgeway Capital Management LLC	34,600	$78K	0.0%	-68.4%	0.160%
8/16/2021	Alberta Investment Management Corp	25,000	$56K	0.0%	N/A	0.116%
8/13/2021	Renaissance Technologies LLC	92,600	$0.21M	0.0%	-24.0%	0.429%
5/21/2021	Citadel Advisors LLC	10,617	$29K	0.0%	N/A	0.053%
5/18/2021	Citadel Advisors LLC	10,617	$29K	0.0%	N/A	0.053%
5/13/2021	Renaissance Technologies LLC	121,849	$0.33M	0.0%	+374.1%	0.611%
5/7/2021	BlackRock Inc.	32,394	$87K	0.0%	+40.6%	0.163%
4/14/2021	WealthTrust Axiom LLC	38,500	$0.10M	0.0%	+234.8%	0.193%
3/26/2021	Susquehanna International Group LLP	14,828	$36K	0.0%	N/A	0.081%
2/17/2021	Canada Pension Plan Investment Board	15,000	$36K	0.0%	N/A	0.082%
2/10/2021	Renaissance Technologies LLC	25,700	$62K	0.0%	N/A	0.140%
2/4/2021	WealthTrust Axiom LLC	11,500	$27K	0.0%	N/A	0.063%

Data available starting January 2016

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $2.77

$2.72

$3.01

50 Day Range

MA: $3.13

$2.75

$3.51

52 Week Range

Now: $2.77

$0.97

$4.00

Volume

401,016 shs

Average Volume

518,696 shs

Market Capitalization

$212.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Who are the company insiders with the largest holdings of Trevi Therapeutics?: Trevi Therapeutics' top insider investors include:
David P Meeker (Director)
Thomas Sciascia (Insider)
Jennifer L Good (CEO)
Lisa Delfini (CFO)
Learn More about top insider investors at Trevi Therapeutics.
Who are the major institutional investors of Trevi Therapeutics?: Trevi Therapeutics' top institutional shareholders include:
MAI Capital Management — 1.83%
Ally Bridge Group NY LLC — 1.72%
Geode Capital Management LLC — 1.64%
State Street Corp — 1.24%
Rosalind Advisors Inc. — 1.03%
Landscape Capital Management L.L.C. — 0.59%
Learn More about top institutional investors of Trevi Therapeutics stock.
Which major investors are selling Trevi Therapeutics stock?: In the last quarter, TRVI stock was sold by these institutional investors:
Rosalind Advisors Inc.
Checkpoint Capital L.P.
Landscape Capital Management L.L.C.
Ally Bridge Group NY LLC
Jane Street Group LLC
During the last year, company insiders that have sold Trevi Therapeutics company stock include:
David P Meeker (Director)
Thomas Sciascia (Insider)
Jennifer L Good (CEO)
Lisa Delfini (CFO)
Learn More investors selling Trevi Therapeutics stock.
Which major investors are buying Trevi Therapeutics stock?: Within the last quarter, TRVI stock was purchased by institutional investors including:
GSA Capital Partners LLP
Geode Capital Management LLC
Fred Alger Management LLC
Barclays PLC
Barclays PLC
State Street Corp
Acuta Capital Partners LLC
SG Americas Securities LLC